2025-07-16 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the provided data. The report is structured to first present the numerical data and then offer a brief analysis for each section.

```markdown
## Johnson & Johnson (JNJ) Stock Analysis
**Ticker:** JNJ
**Company Description:** Johnson & Johnson is a global healthcare company engaged in the research and development, manufacture, and sale of a broad range of products in the healthcare field.

### 1. Performance vs. S&P 500 (VOO)

*   **JNJ Cumulative Return:** 14.31%
*   **VOO Cumulative Return:** 95.00%
*   **Absolute Divergence (JNJ - VOO):** -80.69%
*   **Divergence Range:**  Max: 20.0, Min: -83.0
*   **Relative Divergence:** 3.0

**Analysis:** JNJ has significantly underperformed the S&P 500 (VOO) over the analyzed period. The relative divergence of 3.0 suggests that JNJ's underperformance is near the lower end of its historical range compared to the S&P 500.

**Alpha, Beta Analysis Table:**

| Year       | CAGR   | MDD    | Alpha  | Beta | Cap(B) |
| ---------- | ------ | ------ | ------ | ---- | ------ |
| 2015-2017  | 28.0%  | 56.1%  | -1.0%  | -0.0 | 336.2  |
| 2016-2018  | 8.0%   | 56.6%  | -10.0% | 0.0  | 310.5  |
| 2017-2019  | 18.0%  | 56.6%  | -12.0% | 0.7  | 351.0  |
| 2018-2020  | 12.0%  | 59.2%  | -8.0%  | 0.3  | 378.7  |
| 2019-2021  | 32.0%  | 59.6%  | -16.0% | 0.2  | 411.6  |
| 2020-2022  | 7.0%   | 61.4%  | 5.0%   | 0.2  | 425.0  |
| 2021-2023  | -15.0% | 61.4%  | -33.0% | 0.4  | 377.1  |
| 2022-2024  | -35.0% | 61.4%  | -61.0% | 0.3  | 348.0  |
| 2023-2025  | -13.0% | 70.1%  | -60.0% | 0.2  | 373.4  |

**Analysis:** The table illustrates JNJ's performance over various periods. Key observations:
*   **CAGR:** Fluctuates significantly, showing periods of strong growth and decline. Recent periods show negative CAGR.
*   **MDD:** Maximum Drawdown is consistently high, indicating significant downside risk in all periods.
*   **Alpha:** Generally negative, meaning JNJ has underperformed its benchmark on a risk-adjusted basis in most periods.  There is a +5% positive Alpha for 2020-2022.
*   **Beta:** Relatively low, suggesting lower sensitivity to market movements compared to the S&P 500.  Beta is 0.7 in 2017-2019, but less than 0.5 in all other periods.
*   **Cap(B):** Market capitalization has generally increased but declined in the most recent periods.

### 2. Recent Stock Price Movement

*   **Current Price:** 155.17
*   **Previous Close:** 156.82
*   **Change:** -1.05
*   **5-Day Moving Average:** 156.57
*   **20-Day Moving Average:** 154.13
*   **60-Day Moving Average:** 154.27

**Analysis:** The current price is slightly below the previous close, indicating a minor recent decline. The 5-day moving average is above the 20-day and 60-day moving averages, which *could* signal a short-term upward trend, but the difference is not substantial.

### 3. Market Risk Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.341 (Low Risk)
*   **RSI:** 64.04
*   **PPO:** 0.163
*   **Hybrid Signal:** Cash 0%, Buy 80% of cash (1 share - Caution - MRI:0.34)
*   **20-Day Relative Divergence Change:** +1.3 (Short-term Increase)
*   **Expected Return:** -976%

**Analysis:**
*   **MRI:** Indicates a low-risk environment.
*   **RSI:**  At 64.04, RSI is nearing overbought territory (typically >70), suggesting a potential pullback.
*   **PPO:** The Percentage Price Oscillator (PPO) is at 0.163.
*   **Hybrid Signal:** Recommends a cautious buy signal.
*   **Relative Divergence Change:**  The short-term increase suggests recent improvement in JNJ's performance relative to its history, though it doesn't negate the overall underperformance.
*   **Expected Return:**  The extremely negative expected return suggests significant concerns about JNJ's long-term performance compared to the S&P 500.  This is a *major* red flag.
*   **Price Change Impact:** The decrease from the previous close suggests a recent negative event or sentiment affecting the stock.

### 4. Recent News & Significant Events

*   **2025-07-16:** Business developments, regulatory changes, or market events impacting JNJ.
*   **2025-07-15:** Analysts discussing JNJ's performance and outlook.
*   **2025-07-13:** Notable volatility in JNJ's stock.
*   **2025-07-12:** Market experts highlighting both risks and opportunities.

**Analysis:** Recent news indicates that JNJ is experiencing both significant events and volatility, with analysts actively discussing its performance. This suggests that the stock is currently subject to market scrutiny and potentially facing both positive and negative pressures.

### 5. Recent Earnings Analysis

| 날짜         | EPS  | 매출      |
| ------------ | ---- | --------- |
| 2025-04-23   | 4.57 | 21.89 B$  |
| 2024-10-23   | 1.12 | 22.47 B$  |
| 2024-07-25   | 1.95 | 22.45 B$  |
| 2024-05-01   | 1.35 | 21.38 B$  |
| 2025-04-23   | 1.35 | 21.38 B$  |

**Analysis:** The EPS and revenue figures show some fluctuation, with the most recent EPS being significantly higher than previous quarters. Revenue has been relatively stable.  The duplicate entry for 2025-04-23 with different figures should be investigated.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
| ------------ | ---------- | ------------- |
| 2025-03-31   | \$21.89B  | 66.40%        |
| 2024-12-31   | \$22.52B  | 68.35%        |
| 2024-09-30   | \$22.47B  | 69.01%        |
| 2024-06-30   | \$22.45B  | 69.40%        |
| 2024-03-31   | \$21.38B  | 69.55%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE     |
| ------------ | ---------- | ------- |
| 2025-03-31   | \$78.11B  | 14.08%  |
| 2024-12-31   | \$71.49B  | 4.80%   |
| 2024-09-30   | \$70.16B  | 3.84%   |
| 2024-06-30   | \$71.54B  | 6.55%   |
| 2024-03-31   | \$70.02B  | 4.65%   |

**Analysis:** Revenue has remained relatively stable, although the most recent quarter saw a slight decrease. Profit margins have also shown a slight decline. Equity has increased, and the Return on Equity (ROE) is volatile, with a significant increase in the most recent quarter.

### 7. Overall Analysis & Summary

Johnson & Johnson (JNJ) is currently underperforming the S&P 500 significantly. While the Market Risk Indicator suggests a low-risk environment and the hybrid signal recommends a cautious buy, the extremely negative expected return raises serious concerns about JNJ's long-term investment prospects. Recent news highlights ongoing volatility and market scrutiny. The earnings data shows mixed results, with fluctuating EPS and relatively stable revenue. The financials indicate slight declines in profit margins despite increased equity.

**In summary, a cautious approach is warranted. Further investigation into the factors driving the negative expected return and the reasons for underperformance compared to the S&P 500 is highly recommended before making any investment decisions.**
```
